Overview

Apatinib for Resectable Colorectal Cancer

Status:
Withdrawn

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively. Language: English.

Phase:

N/A

Details

Lead Sponsor:

Nanchong Central Hospital

Treatments:

Apatinib